Laura Zazzeron
Overview
Explore the profile of Laura Zazzeron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dacco V, Gramegna A, Rosazza C, Mariani A, Biffi A, Lanfranchi C, et al.
Lung
. 2024 Nov;
203(1):9.
PMID: 39614886
Purpose: In people with cystic fibrosis (pwCF), elexacaftor/tezacaftor/ivacaftor (ETI) therapy is associated with an average improvement in FEV of 10-14%. However, a subset of individuals fails to achieve a clinically...
2.
Dilena R, Biffi G, Mauri E, Lelii M, Zazzeron L, Bana C, et al.
J Paediatr Child Health
. 2023 Aug;
59(10):1171-1174.
PMID: 37621236
No abstract available.
3.
Grancini V, Gramegna A, Zazzeron L, Alicandro G, Porcaro L, Piedepalumbo F, et al.
Diabetes Metab
. 2023 Aug;
49(5):101466.
PMID: 37536552
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy...
4.
Zazzeron L, Alicandro G, Dacco V, Lanfranchi C, Bulfamante A, Sciarrabba C, et al.
Dig Liver Dis
. 2022 Oct;
55(3):360-365.
PMID: 36253246
Background: Evidence on the effectiveness of proton pump inhibitors (PPI) as adjuvant therapy to improve maldigestion in people with cystic fibrosis (pwCF) is limited and there is increasing concern on...
5.
Calvo-Lerma J, Boon M, Hulst J, Colombo C, Asseiceira I, Garriga M, et al.
Nutrients
. 2021 Jun;
13(6).
PMID: 34073260
Cystic Fibrosis (CF) is a life-long genetic disease, causing increased energy needs and a healthy diet with a specific nutrient distribution. Nutritional status is an indicator of disease prognosis and...
6.
Norsa L, Zazzeron L, Cuomo M, Claut L, Bulfamante A, Biffi A, et al.
Nutrients
. 2019 Aug;
11(8).
PMID: 31412557
Vitamin A is a fundamental micronutrient that regulates various cellular patterns. Vitamin A deficiency (VAT) is a worldwide problem and the primary cause of nocturnal blindness especially in low income...
7.
Battezzati A, Bedogni G, Zazzeron L, Mari A, Battezzati P, Alicandro G, et al.
J Clin Endocrinol Metab
. 2015 Jun;
100(8):2963-71.
PMID: 26057180
Context: Cystic fibrosis (CF) causes an exceptionally high prevalence of diabetes that increases with age, especially in females. The glucose tolerance defect is progressive, but a cystic fibrosis transmembrane conductance...
8.
Crovella S, Segat L, Amato A, Athanasakis E, Bezzerri V, Braggion C, et al.
Clin Chem Lab Med
. 2010 Nov;
49(1):49-54.
PMID: 21077791
Background: The identification of cystic fibrosis (CF) patients who are at greater risk of lung damage could be clinically valuable. Thus, we attempted to replicate previous findings and verify the...
9.
Degiorgio D, Colombo C, Seia M, Porcaro L, Costantino L, Zazzeron L, et al.
Eur J Hum Genet
. 2007 Aug;
15(12):1230-8.
PMID: 17726488
Progressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal-recessive disorder due to mutations in the ATP-binding cassette, subfamily B, member 4 gene (ABCB4). ABCB4 is the liver-specific membrane transporter...
10.
Colombo C, Costantini D, Zazzeron L, Faelli N, Russo M, Ghisleni D, et al.
Acta Paediatr
. 2007 Jun;
96(8):1228-32.
PMID: 17590186
Aim: To study the effect of breastfeeding (BF) on growth, lung function and number of infections during the first 3 years of life in children with cystic fibrosis (CF). Material...